Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2002

View Archived Issues

diaDexus and Emory University form cancer collaboration to target Nox-1 enzyme

Enact reports titanium-based organometallic compounds as anticancer agents

Epothilones: multimedia presentation of mechanisms of action in Part II of an Integrity Case Study

Phase III trial of tecadenoson in PSVT meets primary endpoint

La Jolla set to complete LJP-394 phase III enrollment

Improved quality of life reported for long-acting risperidone in schizophrenia

License agreement for Collagenex's IMPACS compounds for aortic aneurysms

Potential use of a new conjugated estrogen tablet for postmenopausal hot flushes

Genaera provides Lomucin update in cystic fibrosis and asthma

Novel macrolide antibiotics covered by Enanta patent

AstraZeneca presents novel GnRH antagonists for cancer, BPH and uterine myoma

GlaxoSmithKline licenses Kissei's selective inhibitors of renal glucose transport for diabetes

CYP1B1-activated prodrugs of antitumor compound identified by U. of London researchers

Clofarabine enters phase I/II trial in combination with ara-C

French researchers describe 5-HT4 ligands with potential in GI and other disorders

Novel antiproliferative agents prepared at Temple University

New DHFR inhibitors in early development at Melacure

NCX-4016 IND cleared for phase II

Rega Institute claims novel antiviral compounds

GSK and Biovitrum collaborate on 5-HT2C receptor agonists for obesity and other disorders

Inhibitor of p56lck tyrosine kinase and its use in rheumatoid arthritis

Interim results from phase II gastric cancer trial of pemtumomab presented

First potent inhibitors of glutamate racemase with antipneumococcal activity

Anti-fstZ PNA molecule with activity against Gram-negative bacteria

Antidiabetic, hypolipidemic and insulin-sensitizing properties described for novel thiazolidinedione

Baxter submits MAA in E.U. for rAHF-PFM

Prandin approved as combination therapy with rosiglitazone or pioglitazone for type 2 diabetes

Amylin withdraws Symlin MAA in E.U. with plans to resubmit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...